Healthcare Industry News: Age-related Macular Degeneration
News Release - February 9, 2006
Clarus Ventures Expands Investment TeamCAMBRIDGE, Mass. and SAN FRANCISCO, Feb. 9 (HSMN NewsFeed) -- Clarus Ventures, LLC, a global lifesciences venture capital firm, today announced the addition of three Principals and a Controller to its investment team.
Emmett Cunningham, MD, Ph.D., M.P.H., Michele Park, Ph.D., and Scott Requadt, JD, MBA, have joined the firm as Principals. Danielle Bechard has joined the firm as Controller.
"We are fortunate to have attracted such high caliber individuals to help evaluate, grow and nurture our investments. Members of our team had previous relationships with both Emmett Cunningham and Scott Requadt, when they were at Eyetech and TransForm, respectively. It is a pleasure to be working with them again," said Dr. Dennis Henner, Managing Director of Clarus Ventures.
Prior to joining the San Francisco office of Clarus Ventures, Dr. Emmett Cunningham was Senior Vice President, Medical Strategy at Eyetech Pharmaceuticals, Inc. At Eyetech, Dr. Cunningham played a leadership role in the development and approval of Macugen for Age-related Macular Degeneration. Before that, Dr. Cunningham conducted clinical research at Pfizer, Inc. As an ophthalmologist specializing in infectious and inflammatory eye disease, Dr. Cunningham most recently served as Clinical Professor of Ophthalmology at New York University School of Medicine, having also held a tenured position at the University of California-San Francisco. Dr. Cunningham received his M.D. from Johns Hopkins University, his Ph.D. in neuroscience from the University of California-San Diego, and his M.P.H. in epidemiology and statistics from Johns Hopkins University.
Dr. Michele Park joins the San Francisco office of Clarus Ventures from Credit Suisse First Boston where she was an analyst covering large, medium and small capitalization biotechnology companies with a focus on companies with oncologic and anti-infective products. Dr. Park began her career as a biotechnology analyst at Piper Jaffrey covering small and mid capitalization companies. Dr. Park received her Ph.D. in molecular biology from Memorial Sloan Kettering Institute.
Mr. Scott Requadt joins the Cambridge office of Clarus Ventures from TransForm Pharmaceuticals, Inc. where he was Director of Business Development, negotiating over ten corporate partnerships, overseeing a portfolio of over 200 patents and applications, and playing a critical role in the acquisition of TransForm by Johnson & Johnson. Prior to TransForm, Mr. Requadt was a Mergers & Acquisitions attorney at Davis Polk & Wardwell in New York. Mr. Requadt received his JD degree from the University of Toronto and his MBA degree from Harvard Business School.
Danielle Bechard also joins the Cambridge office of Clarus Ventures as Controller. Ms. Bechard joins Clarus from the McDonald's Corporation where she was responsible for franchisee analysis. Before that, Ms. Bechard was senior auditor in the venture capital group of Price Waterhouse Coopers.
About Clarus Ventures:
Founded by a group of accomplished investment professionals with extensive and complementary industry backgrounds, Clarus Ventures is a life sciences venture capital firm with a team that has a long history of success in creating value. Deep relationships with industry thought leaders and decision makers allow this team to identify unique investment opportunities and shepherd them to maturity. Clarus augments its core expertise of investing in biopharmaceuticals and medical technology with deep and diverse expertise in research and development, commercialization, business development and operations management at the global level. The Firm manages $500 million through its inaugural fund, Clarus Lifesciences I, L.P. and has offices in Cambridge, MA and San Francisco, CA.
For additional information on Clarus Ventures please visit http://www.clarusventures.com.
Source: Clarus Ventures
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.